Drug profile · INN
nicotine
NICODERM CQ
- US status
- approved
- Patents linked
- 8
- News articles
- 0
Quick answer
nicotine (NICODERM CQ) is an FDA-listed pharmaceutical active ingredient. Route of administration: nasal. Current US regulatory status: approved.
Key facts
Related patents
Search patents →-
US 11712467
Methods of rational nicotine hapten design and uses thereof
granted -
US 11597916
Nicotine degrading enzyme variants
granted -
US 11357848
Methods of rational nicotine hapten design and uses thereof
granted -
US 10182994
Nanoparticulate complex of nicotine and cerium oxide and use thereof
granted -
US 9884114
Methods of rational nicotine hapten design and uses thereof
granted -
US 7547712
Methods for decreasing the toxic effects of nicotine on fetuses in pregnant women
granted -
US 7037533
Functional agent for decomposing nicotine and method of preparing the same
expired -
US 6846817
Nicotine receptor ligands
expired
Frequently asked questions
What is nicotine?
nicotine (NICODERM CQ) is an FDA-listed pharmaceutical active ingredient. Route of administration: nasal. Current US regulatory status: approved.
What is the brand name for nicotine?
NICODERM CQ is a marketed brand name for nicotine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of nicotine?
nicotine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.